U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT06930872) titled 'Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates' on April 09.
Brief Summary: This study is an open-label drug-drug interaction (DDI) study of ZYN002 transdermal gel and multiple drugs.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Drug Interaction
Intervention:
DRUG: Part 1
ZYN002 (transdermal), midazolam (oral), omeprazole (oral), losartan (oral), dextromethorphan (oral), caffeine (oral), repaglinide (oral), bupropion (oral)
DRUG: Part 2
ZYN002 (transdermal), VPA (oral)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Harmony Biosciences Management, Inc.
Published by HT Digital ...